This study is a Phase 3 clinical trial which aims to evaluate the effect of brensocatib (study drug) at 10mg and 25mg compared with no study drug on the rate of pulmonary exacerbations (chest flare-ups) over the 52-week treatment period.
To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at email@example.com or phone 6151 0888.
Eligibility & Requirements
- Aged between 18 and 85 with a diagnosis of non-cystic fibrosis bronchiectasis.
- At least two flare-ups of your bronchiectasis requiring antibiotic treatment in the last 12 months.
- The phase 3 clinical trial will run for up to 62 weeks. During this period you will be required to attend up to 8 visits to Sir Charles Gairdner Hospital and complete 4 phone calls.